Friday, 6 April 2018

Hospital Infection Therapeutics Market is increasing at a significant rate | Global Industry Scope in Future


The hospital infection therapeutics market is increasing at a significant rate, due to high susceptibility of neonatal population in healthcare setting and high occurrence of numerous hospital infections. Increasing incidences of hospital infections, high number of pipeline drug molecules for specific treatment of healthcare associated infections and high unaddressed needs in most of the countries are some of the factors providing ample opportunities for the hospital infection therapeutics market to grow in the coming years.


North America leads the Hospital Infection Therapeutics Market followed by Europe. The North America hospital infection therapeutics market leads, due to improved healthcare awareness, high ratio of hospitals as compared to population of the region, increasing count of multi drug resistant microbial pathogens and increase in aging population of the region. Asia-Pacific is growing with an exponential rate, due to increased incidences of hospital infections and high demands of therapeutic drugs in the emerging countries such India and China.


On the basis of infection types, the hospital infection therapeutics market can be categorized into hospital acquired pneumonia, urinary tract infections, bloodstream infections, surgical site infections and gastrointestinal disorders. Hospital acquired pneumonia leads the global hospital infection therapeutics market, under the types of infection categories. While urinary tract infections are expected to grow at an exponential rate in the coming years.

 Some of the competitors in the hospital infection therapeutics market are: Cubist Pharmaceuticals, Inc., Actavis PLC, Johnson & Johnson Services, Inc., Bayer AG, GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Merck & Co., Inc., AstraZeneca PLC, Pfizer, Inc. and Sanofi.
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)